Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03912974

Organisation Name: University Hospital, Basel, Switzerland

Overal Status: Active, not recruiting

Start Date: July 4, 2019

Last Update: October 27, 2020

Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary: Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram are first-line treatments for depression. They inhibit the serotonin transporter (SERT). This might cause a possible downregulation of postsynaptic 5-HT receptors, e.g. the 5-HT2A receptor. The aim of the study is to investigate the effects of psilocybin after escitalopram and Placebo pretreatment. Subjective and physiological effects as well as effects on gene expression will be assessed.

Conditions:
  • Healthy


Total execution time in seconds: 0.37358713150024